La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. It offers GIAPREZA, an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock. The company is developing LJPC-401, a formulation of synthetic human hepcidin for the treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease, and myelodysplastic syndrome. La Jolla Pharmaceutical Company was founded in 1989 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:LJPC
CUSIPN/A
Phone858-207-4264
Debt
Debt-to-Equity RatioN/A
Current Ratio13.05
Quick Ratio13.00
Price-To-Earnings
Trailing P/E Ratio-4.22
Forward P/E Ratio-3.07
P/E GrowthN/A
Sales & Book Value
Annual Sales$620,000.00
Price / Sales966.70
Cash FlowN/A
Price / CashN/A
Book Value$3.68 per share
Price / Book6.21
Profitability
EPS (Most Recent Fiscal Year)($5.41)
Net Income$-114,800,000.00
Net MarginsN/A
Return on Equity-147.98%
Return on Assets-94.78%
Miscellaneous
Employees309
Outstanding Shares26,230,000
Market Cap$608.45 million
La Jolla Pharmaceutical (NASDAQ:LJPC) Frequently Asked Questions
What is La Jolla Pharmaceutical's stock symbol?
La Jolla Pharmaceutical trades on the NASDAQ under the ticker symbol "LJPC."
How were La Jolla Pharmaceutical's earnings last quarter?
La Jolla Pharmaceutical (NASDAQ:LJPC) posted its earnings results on Wednesday, August, 8th. The biopharmaceutical company reported ($2.02) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.95) by $0.07. The biopharmaceutical company had revenue of $1.59 million for the quarter, compared to analysts' expectations of $2.48 million. View La Jolla Pharmaceutical's Earnings History.
When is La Jolla Pharmaceutical's next earnings date?
What price target have analysts set for LJPC?
6 equities research analysts have issued 12 month target prices for La Jolla Pharmaceutical's shares. Their predictions range from $21.00 to $115.00. On average, they expect La Jolla Pharmaceutical's stock price to reach $51.8333 in the next twelve months. This suggests a possible upside of 126.8% from the stock's current price. View Analyst Price Targets for La Jolla Pharmaceutical.
What is the consensus analysts' recommendation for La Jolla Pharmaceutical?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for La Jolla Pharmaceutical in the last year. There are currently 2 sell ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for La Jolla Pharmaceutical.
What are Wall Street analysts saying about La Jolla Pharmaceutical stock?
Here are some recent quotes from research analysts about La Jolla Pharmaceutical stock:
- 1. According to Zacks Investment Research, "LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products for the treatment of autoimmune and inflammatory diseases. " (8/15/2018)
- 2. HC Wainwright analysts commented, "We base our $53 price target on a sum-of-the-parts analysis based on (1) the P/E value of La Jolla’s current commercial business (Giapreza), (2) an NPV of its pipeline (LJPC-401), and (3) our estimated year-end fully diluted net cash of $3.66/share, which includes the capital raise earlier this year and the royalty agreement, to arrive at our price target. We value the current commercial business at $39.78 per share, and the pipeline at $9.14 per share. The commercial business value is based on a P/E multiple assumption of 30x our 2023E EPS of $2.02, discounted at 15%." (8/9/2018)
- 3. Chardan Capital analysts commented, "We note that Protagonist Therapeutics (unrated) has also presented data on its hepcidin mimetic, PTG-300, a potential competitor of LJPC-401. Protagonist’s EHA abstract indicated that PTG-300 in healthy volunteers leads to longer suppression of iron levels when compared to LJPC-401. We note that LJPC-401 is naturally-occurring while PTG-300 is a mimetic to the natural peptide (see S-1), which could potentially lead to antibodies against the unnatural PTG-300. La Jolla reported analysis of samples from its clinical trials has not shown antibodies to LJPC-401. The data shown Please refer to important disclosure information and Regulation Analyst Certification found on pages 14 – 16 of this report.by Protagonist seem to also indicate a potential plateauing effect at the 20 mg dose, akin to what was seen in the La Jolla study." (6/18/2018)
Who are some of La Jolla Pharmaceutical's key competitors?
Some companies that are related to La Jolla Pharmaceutical include Crispr Therapeutics (CRSP), Spark Therapeutics (ONCE), Acceleron Pharma (XLRN), Regenxbio (RGNX), Repligen (RGEN), Momenta Pharmaceuticals (MNTA), Rubius Therapeutics (RUBY), Atara Biotherapeutics (ATRA), Sangamo Therapeutics (SGMO), Denali Therapeutics (DNLI), Editas Medicine (EDIT), Iovance Biotherapeutics (IOVA), Solid Biosciences (SLDB), Audentes Therapeutics (BOLD) and Coherus Biosciences (CHRS).
Who are La Jolla Pharmaceutical's key executives?
La Jolla Pharmaceutical's management team includes the folowing people:
- Dr. George F. Tidmarsh, Pres, CEO, Sec. & Director (Age 58)
- Mr. Dennis M. Mulroy, Chief Financial Officer (Age 63)
- Ms. Jennifer A. Carver, Chief Operating Officer (Age 64)
- Mr. James M. Rolke, Chief Scientific Officer (Age 49)
- Dr. Lakhmir S. Chawla, Chief Medical Officer (Age 47)
Has La Jolla Pharmaceutical been receiving favorable news coverage?
Press coverage about LJPC stock has been trending somewhat positive on Sunday, Accern Sentiment reports. Accern identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. La Jolla Pharmaceutical earned a news impact score of 0.12 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 47.56 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View Recent Headlines for La Jolla Pharmaceutical.
Who are La Jolla Pharmaceutical's major shareholders?
La Jolla Pharmaceutical's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (13.99%), Jennison Associates LLC (12.19%), Scopia Capital Management LP (9.85%), BlackRock Inc. (5.56%), RTW Investments LP (5.13%) and Oak Ridge Investments LLC (0.74%). Company insiders that own La Jolla Pharmaceutical stock include Dennis Mulroy, George F Tidmarsh, Jennifer Carver, Kevin C Tang, Lakhmir S Chawla, Laura L Douglass, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Institutional Ownership Trends for La Jolla Pharmaceutical.
Which institutional investors are selling La Jolla Pharmaceutical stock?
LJPC stock was sold by a variety of institutional investors in the last quarter, including Oak Ridge Investments LLC, Trexquant Investment LP, Stanley Laman Group Ltd., California Public Employees Retirement System and GSA Capital Partners LLP. View Insider Buying and Selling for La Jolla Pharmaceutical.
Which institutional investors are buying La Jolla Pharmaceutical stock?
LJPC stock was acquired by a variety of institutional investors in the last quarter, including Scopia Capital Management LP, BlackRock Inc., RTW Investments LP, FMR LLC, Jennison Associates LLC, Bank of America Corp DE, Schwab Charles Investment Management Inc. and Employees Retirement System of Texas. Company insiders that have bought La Jolla Pharmaceutical stock in the last two years include Dennis Mulroy, George F Tidmarsh, Jennifer Carver, Kevin C Tang, Lakhmir S Chawla, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for La Jolla Pharmaceutical.
How do I buy shares of La Jolla Pharmaceutical?
Shares of LJPC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is La Jolla Pharmaceutical's stock price today?
One share of LJPC stock can currently be purchased for approximately $22.85.
How big of a company is La Jolla Pharmaceutical?
La Jolla Pharmaceutical has a market capitalization of $608.45 million and generates $620,000.00 in revenue each year. The biopharmaceutical company earns $-114,800,000.00 in net income (profit) each year or ($5.41) on an earnings per share basis. La Jolla Pharmaceutical employs 309 workers across the globe.
How can I contact La Jolla Pharmaceutical?
La Jolla Pharmaceutical's mailing address is 4550 TOWNE CENTRE COURT, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-207-4264 or via email at [email protected]
MarketBeat Community Rating for La Jolla Pharmaceutical (NASDAQ LJPC)
MarketBeat's community ratings are surveys of what our community members think about La Jolla Pharmaceutical and other stocks. Vote "Outperform" if you believe LJPC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LJPC will underperform the S&P 500 over the long term. You may vote once every thirty days.
